We’re sorry, something doesn't seem to be working properly.
Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.
Difficult diagnosis and genetic analysis of fibrodysplasia ossificans progressiva: a case report
BMC Medical Geneticsvolume 19, Article number: 30 (2018)
Fibrodysplasia ossificans progressiva (FOP), an ultra-rare and disabling genetic disorder of skeletal malformations and progressive heterotopic ossification, is caused by heterozygous activating mutations in activin A receptor, type I/activin-like kinase 2 (ACVR1/ALK2). The rarity of the disease makes it common to make a misdiagnosis and cause mismanagement.
We reported a case of a sixteen-year-old male patient who had suffered from pain and swelling in the biopsy site for two months. His physical examination presented serious stiffness and multiple bony masses in the body, with his bilateral halluces characterized by hallux valgus deformity and macrodactyly. Imaging examinations showed widespread heterotopic ossification. All laboratory blood tests were normal except for the one on alkaline phosphatase. A de novo heterozygous mutation (c.617G > A; p.R206H) were found in the ACVR1/ALK2 using gene sequencing.
Even though FOP is a rare disorder of genetic origin, which is generally misdiagnosed, the genetic analysis could provide definitive confirmation of the disease. Awareness of such an important approach can help clinicians to avoid the commonly practiced misdiagnosis and mismanagement of the rare disease.
Fibrodysplasia ossificans progressiva (FOP; MIM #135100) is an extreme-rare and disabling autosomal dominant disorder characterized by congenital malformation of the great toes and progressive heterotopic ossification [1,2,3,4]. In FOP, the progressive heterotopic ossification, which begins in the first decade of life, is episodic, resulting from flare-ups that occur spontaneously or secondary to trauma [5, 6]. The bone formation leads subsequently to a severe ankylosis of the spine, limbs and jaw, with an unpredictable progression of the disability and mortality from cardiorespiratory complications around the fourth decade of life [3, 7]. Because of the rarity of FOP, most patients are misdiagnosed to have unnecessary biopsies performed, and to undergo intramuscular injections or surgical excisions of ectopic bone, which can trigger episodes of explosive heterotopic ossification [6, 8, 9]. Nonetheless, it has recently been shown that FOP is caused by heterozygous activating mutations in activin A receptor, type I/activin-like kinase 2 (ACVR1/ALK2), which is a bone morphogenetic protein (BMP) type I receptor [10,11,12]. Based on these findings, DNA sequence analysis of ACVR1/ALK2 of suspected patients can confirm the diagnosis of FOP, thus avoiding misdiagnosis and mismanagement . In the current case report, we managed a sixteen-year-old male patient with the classic features of FOP by making a genetic analysis so that we presented a deep insight into the diagnosis of this rare disorder.
The current case report was presented in accordance with the CARE guidelines. A sixteen-year-old male patient was brought to our emergency room with the complaints of pain and swelling in his upper back, in which a biopsy had been performed two months before. At the age of 9, the patient developed tender stiffness of his shoulders and neck. Over the next 4 years, he experienced multiple similar swellings on the upper back; subsequently, the movement of the shoulders and neck was limited, and masses grew progressively. The patient went to the specialists at some local hospitals for examination and treatment, and they managed the patient without making a confirmative diagnosis. Two months before, one of these doctors arranged a biopsy for the patient, but the results of the pathological examination only revealed that the mass was heterotopic ossification, the cause of which was unclear.
The physical examination presented serious stiffness with a tiny range of motion in the patient’s neck and shoulders; multiple bony masses with irregular sizes on the neck, back and buttocks; bilateral halluces characterized by hallux valgus deformity with macrodactyly, which was more serious on the left side; and fused interphalangeal joints of both halluces. The biopsy site was marked tenderness and swelling. The imaging examinations showed widespread heterotopic ossification in the cervical spine, shoulder girdles and thorax (Fig. 1). As indicated by the radiograph of the cervical spine, the bony bridge formation was visible in the nuchal ligament, which may have predominantly contributed to the neck ankylosis (Fig. 2). The computerized tomography (CT) scan found several initial heterotopic ossification lesions in the pectoralis major and serratus anterior (Fig. 3). Dorso-plantar radiograph indicated that the bilateral feet developed characteristic clinical features of FOP: hallux valgus and fusion of the halluces’ interphalangeal joint (Fig. 4). As indicated by the laboratory blood tests, alkaline phosphatase was 276 (45–125) U/L, while serum calcium, phosphorus, hemoglobin, erythrocyte sedimentation rate, C-reactive protein, liver enzymes, urea, creatinine and parathyroid hormone were all within normal limits. From the other hospital, the biopsy section revealed the features of inflammatory fibroproliferative and osteogenic neoplasm (Fig. 5).
Based on the patient’s history and the results of the examinations and tests, we considered FOP as a possible diagnosis. Therefore, we collected the patient’s and his parents’ blood samples for the DNA sequence analysis of ACVR1/ALK2. The gene sequencing showed that the patient had a de novo heterozygous mutation (c.617G > A; p.R206H) in ACVR1/ALK2, which was however not detected in his parents (Fig. 6). Consequently, the diagnosis FOP was confirmed when the canonical ACVR1/ALK2 c.617G > A (p.R206H) mutation was detected in the patient.
We administered a co-therapy of a high dose of glucocorticoids (methylprednisolone, 500 mg/d for 3 days) and cyclo-oxygenase-2 inhibitors (celecoxib 200 mg/d) to relieve pain and swelling in the biopsy site. Furthermore, we advised the patient to avoid trauma in daily activities. At the follow-up one month later, we found that the pain had been relieved, but the biopsy site was still swollen.
Discussion and conclusion
FOP is one of the rarest diseases with a worldwide prevalence of approximately 1:2,000,000, and without any racial or geographic preponderance [1, 14]. Considering the size of Chinese populations, we could estimate the incidence of at least 650 patients in China [5, 15], but only a small number of FOP cases have been reported from China [16, 17]. Actually, the vast majority of Chinese medical workers know little about the rare disease and lacked clinical experiences in diagnosing FOP so that many FOP patients were misdiagnosed or underwent unnecessary diagnostic biopsies , just as indicated by the current case report. It is important that a growing number of clinicians know about FOP. If the patient is observed to have developed malformed great toes and heterotopic ossification, the physician should make a genetic analysis rather than conduct a biopsy [9, 10].
In 2006, Shore et al. succeeded in locating the causative gene of FOP on chromosome 2q23-24 by genome-wide linkage analysis, and recognized the same heterozygous mutation (c.617G > A; p.R206H) in the glycine-serine (GS) activation domain of ACVR1/ALK2 which encodes a type I BMP transmembrane receptor . In a normal individual, AVCR1 receptor binds an antagonist of BMP, and a muscle cell or a fibroblast does not differentiate into a bone or cartilage cell. In a FOP patient, however, the “gain of function” mutation of AVCR1 receptor makes it capable to bind BMP molecules, thereby opening BMP signal Smad pathway, increasing BMP signal inhibition, causing BMP mRNA and protein overexpression, and finally inducing the cell differentiation .
The management of FOP is fundamentally characterized by prevention, which includes the avoidance of trauma, deep intramuscular injections, invasive biopsies, and excision procedures for heterotopic masses [6, 20]. Up to now, however, no medical treatment is available to alter the natural history of the disease [1, 21]. High dose glucocorticoids, nonsteroidal anti-inflammatory medications, cyclo-oxygenase-2 inhibitors, leukotriene inhibitors and mast cell stabilizers have been reported to exert the effect of limited relief on chronic pain and inflammatory flare-ups [20, 22]. While definitive treatments are not yet available, the recent studies on the FOP gene and the pathophysiology of ACVR1/ALK2-mediated heterotopic ossification have documented novel approaches to the prevention and treatment of FOP [11, 23, 24]. Typically, FOP has such features as malformed great toes and heterotopic ossification. Because of its rarity, nevertheless, FOP is often misdiagnosed, as further indicated by the current case report in which the patient had received a misdiagnosis and undergone improper treatment until a genetic analysis was made to confirm the diagnosis of FOP. It is imperative that physicians have a better understanding of this extremely rare disease and be aware of an important role the genetic analysis plays in the diagnosis of the disease so that they can manage the disorder properly.
Activin A receptor, type I
Activin-like kinase 2
Bone morphogenetic protein
Fibrodysplasia ossificans progressiva
Kaplan FS, Le Merrer M, Glaser DL, Pignolo RJ, Goldsby RE, Kitterman JA, Groppe J, Shore EM. Fibrodysplasia ossificans progressiva. Best Pract Res Clin Rheumatol. 2008;22(1):191–205.
Schroeder HW Jr, Zasloff M. The hand and foot malformations in fibrodysplasia ossificans progressiva. Johns Hopkins Med J. 1980;147(2):73–8.
Smith R, Athanasou NA, Vipond SE. Fibrodysplasia (myositis) ossificans progressiva: clinicopathological features and natural history. QJM. 1996;89(6):445–6.
Cohen RB, Hahn GV, Tabas JA, Peeper J, Levitz CL, Sando A, Sando N, Zasloff M, Kaplan FS. The natural history of heterotopic ossification in patients who have fibrodysplasia ossificans progressiva. A study of forty-four patients. J Bone Joint Surg Am. 1993;75(2):215–9.
Zhang W, Zhang K, Song L, Pang J, Ma H, Shore EM, Kaplan FS, Wang P. The phenotype and genotype of fibrodysplasia ossificans progressiva in China: a report of 72 cases. Bone. 2013;57(2):386–91.
Pignolo RJ, Bedford-Gay C, Liljesthrom M, Durbin-Johnson BP, Shore EM, Rocke DM, Kaplan FS. The natural history of flare-ups in fibrodysplasia ossificans progressiva (FOP): a comprehensive global assessment. J Bone Miner Res. 2016;31(3):650–6.
Kaplan FS, Zasloff MA, Kitterman JA, Shore EM, Hong CC, Rocke DM. Early mortality and cardiorespiratory failure in patients with fibrodysplasia ossificans progressiva. J Bone Joint Surg Am. 2010;92(3):686–91.
Kitterman JA, Kantanie S, Rocke DM, Kaplan FS. Iatrogenic harm caused by diagnostic errors in fibrodysplasia ossificans progressiva. Pediatrics. 2005;116(5):e654–61.
Kamal AF, Novriansyah R, Rahyussalim, Prabowo Y, Siregar NC. Fibrodysplasia Ossificans Progressiva: difficulty in diagnosis and management a case report and literature review. J Orthop Case Rep. 2015;5(1):26–30.
Kaplan FS, Xu M, Seemann P, Connor JM, Glaser DL, Carroll L, Delai P, Fastnacht-Urban E, Forman SJ, Gillessen-Kaesbach G, et al. Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1. Hum Mutat. 2009;30(3):379–90.
Barruet E, Morales BM, Lwin W, White MP, Theodoris CV, Kim H, Urrutia A, Wong SA, Srivastava D, Hsiao EC. The ACVR1 R206H mutation found in fibrodysplasia ossificans progressiva increases human induced pluripotent stem cell-derived endothelial cell formation and collagen production through BMP-mediated SMAD1/5/8 signaling. Stem Cell Res Ther. 2016;7(1):115.
Kaplan FS, Seemann P, Haupt J, Xu M, Lounev VY, Mullins M, Shore EM. Investigations of activated ACVR1/ALK2, a bone morphogenetic protein type I receptor, that causes fibrodysplasia ossificans progressiva. Methods Enzymol. 2010;484:357–73.
Lakkireddy M, Chilakamarri V, Ranganath P, Arora AJ, Vanaja MC. Clinical and genetic analysis of fibrodysplasia ossificans progressiva: a case report and literature review. J Clin Diagn Res. 2015;9(8):RD01–3.
Pignolo RJ, Shore EM, Kaplan FS. Fibrodysplasia ossificans progressiva: clinical and genetic aspects. Orphanet J Rare Dis. 2011;6:80.
Zhou Q, Meng Y, Su L, Zhao SM, Shi HP, Huang SZ. A Chinese girl with fibrodysplasia ossificans progressiva caused by a de novo mutation R206H in ACVR1 gene. Zhonghua Er Ke Za Zhi. 2008;46(3):215–9.
Zhang RY, Wang J, Li Q. Report of a case with multiple myositis ossificans progressiva. Zhonghua Er Ke Za Zhi. 2006;44(2):146.
Liu JX, Hu R, Sun Y, Jiang H. General anesthesia in fibrodysplasia ossificans progressive: a case report and clinical review. Int J Clin Exp Med. 2014;7(5):1474–9.
Shore EM, Xu M, Feldman GJ, Fenstermacher DA, Cho TJ, Choi IH, Connor JM, Delai P, Glaser DL, LeMerrer M, et al. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet. 2006;38(5):525–7.
Bouvard B, Masson C, Legrand E, Audran M. Fibrodysplasia ossificans progressiva. A case report and focus on the BMP signaling pathway. Morphologie. 2016;100(331):250–5.
Pignolo RJ, Shore EM, Kaplan FS. Fibrodysplasia ossificans progressiva: diagnosis, management, and therapeutic horizons. Pediatr Endocrinol Rev. 2013;10(Suppl 2):437–48.
Rashid U, Bari A, Maqsood A, Naz S, Ahmad TM. Fibrodysplasia Ossificans Progressiva. J Coll Physicians Surg Pak. 2016;26(2):154–5.
Kaplan FS, Pignolo RJ, Shore EM. From mysteries to medicines: drug development for fibrodysplasia ossificans progressive. Expert Opin Orphan Drugs. 2013;1(8):637–49.
Kaplan FS, Groppe J, Shore EM. When one skeleton is enough: approaches and strategies for the treatment of fibrodysplasia ossificans progressiva (FOP). Drug Discov Today Ther Strateg. 2008;5(4):255–62.
Yu PB, Deng DY, Lai CS, Hong CC, Cuny GD, Bouxsein ML, Hong DW, McManus PM, Katagiri T, Sachidanandan C, et al. BMP type I receptor inhibition reduces heterotopic [corrected] ossification. Nat Med. 2008;14(12):1363–9.
The authors wish to thank the patient’s family for their cooperation in the study.
This work was supported by a grant from the Seed Fund Program of Shanghai University of Medicine & Health Sciences (HMSF-17-22-044).
Availability of data and materials
All of the data appeared within the manuscript.
Ethics approval and consent to participate
This study was approved by the Ethics Committee of Shanghai University of Medicine & Health Sciences Affiliated Zhoupu Hospital, Shanghai, China.
Consent for publication
A written informed consent was obtained from the parents of the patient for publication of this case report and any accompanying images.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.